Search results for "Esomeprazole"

showing 10 items of 13 documents

Impact of dual antiplatelet therapy with proton pump inhibitors on the outcome of patients with acute coronary syndrome undergoing drug-eluting stent…

2012

This study aimed to assess if proton pump inhibitors (PPIs) may reduce the effectiveness of clopidogrel, than H2 antagonist (anti-H2) in order to determine rehospitalization for acute coronary syndrome (re-ACS), target vessel revascularization (TVR) and cardiac death. This case-control study included 176 patients with ACS undergoing angioplasty (PCI) with drug-eluting stent implantation. The population was divided into two groups: PPI group (n=121) consisting of patients receiving at discharge dual antiplatelet therapy (DAT) plus PPI and anti-H2 group (n=55), consisting of patients receiving at discharge DAT + H2 receptor antagonist (H2RA). In a followup of 36 months the prevalence of ACS e…

Acute coronary syndromemedicine.medical_specialtyeducation.field_of_studyArticle Subjectbusiness.industrymedicine.medical_treatmentPopulationmedicine.diseaseClopidogrelEsomeprazoleSurgeryantiplatelet therapy PPIs clopidogrel anti-H2 ACS PCIDrug-eluting stentInternal medicineAngioplastyConventional PCImedicineCardiologyClinical StudyeducationbusinessOmeprazolemedicine.drug
researchProduct

Efficacy of naproxen with or without esomeprazole for pain and inflammation in patients after bilateral third molar extractions: a double blinded cro…

2017

Background Using a double-blinded randomized crossover design, this study aimed to evaluate acute postoperative pain management, swelling and trismus in 46 volunteers undergoing extractions of the two lower third molars, in similar positions, at two different appointments who consumed a tablet of either NE (naproxen 500 mg + esomepraz ole 20 mg) or only naproxen (500 mg) every 12 hours for 4 days. Material and Methods Parameters were analyzed: self-reported pain intensity using a visual analog scale (VAS) pre- and postoperative mouth opening; incidence, type and severity of adverse reactions; total quantity consumed of rescue medication; and pre- and postoperative swelling. Results Female v…

AdultMaleMolarNaproxenmedicine.medical_specialtyAdolescentVisual analogue scaleTrismuslaw.inventionEsomeprazoleYoung Adult03 medical and health sciencesCOMPLICAÇÕES PÓS-OPERATÓRIASNaproxen0302 clinical medicinePharmacotherapyDouble-Blind MethodRandomized controlled triallawHumansPain ManagementMedicineGeneral DentistryInflammationPain PostoperativeCross-Over Studiesbusiness.industryResearchAnti-Inflammatory Agents Non-SteroidalEsomeprazoleProton Pump Inhibitors:CIENCIAS MÉDICAS [UNESCO]Crossover studySurgeryTreatment OutcomeOtorhinolaryngology030220 oncology & carcinogenesisAnesthesiaUNESCO::CIENCIAS MÉDICASTooth ExtractionDrug Therapy CombinationFemaleMolar ThirdSurgeryOral Surgerymedicine.symptombusiness030217 neurology & neurosurgerymedicine.drug
researchProduct

Effect of intravenous application of esomeprazole 40???mg versus pantoprazole 40???mg on 24-hour intragastric pH in healthy adults

2007

BACKGROUND: It has been demonstrated that therapy with proton pump inhibitors reduces recurrence of bleeding following initial endoscopic treatment of bleeding peptic ulcers. AIM: This study compared the effects of esomeprazole 40 mg and pantoprazole 40 mg on intragastric acid control. Both substances were administered intravenously as 15-min infusion and as bolus injection. METHODS: Healthy men and women volunteers were enrolled in this single-center, open, randomized, three-way crossover study. After administration of esomeprazole 40 mg and pantoprazole 40 mg intravenously as 15-min infusion, and pantoprazole 40 mg intravenously as bolus injection, continuous 24-h intragastric pH monitori…

AdultMalemedicine.medical_specialtymedicine.drug_classPepticProton-pump inhibitorPharmacologyGastroenterology2-PyridinylmethylsulfinylbenzimidazolesHelicobacter InfectionsEsomeprazoleGastric AcidInternal medicineHumansMedicineEsomeprazole SodiumInfusions IntravenousPantoprazoleMonitoring PhysiologicPantoprazoleCross-Over StudiesHelicobacter pyloriHepatologybusiness.industryStomachGastroenterologyEsomeprazoleGastric Acidity DeterminationHydrogen-Ion ConcentrationMiddle AgedAnti-Ulcer AgentsCrossover studymedicine.anatomical_structureInjections IntravenousBody ConstitutionGastric acidFemalebusinessmedicine.drugEuropean Journal of Gastroenterology & Hepatology
researchProduct

Uso degli inibitori di pompa protonica in un Policlinico Universitario

2012

Summary Introduction Proton pump inhibitors (PPIs) are highly prescribed drugs in Italy and in particular in the Sicilian region but little is known about their use in the hospital setting. Materials and methods PPI utilization and related costs were reviewed retrospectively by examining the pharmaceutical records of drug dispensation to the various wards of the Policlinico Universitario P. Giaccone of Palermo in 2010. Differences in the prescribing rates and drug preferences among the different clinical wards were analyzed. Results A total of 20,420 patients were hospitalized at the Policlinico of Palermo in 2010. Overall, the consumption of PPIs was 120 DDD/100 bed-days for the year 2010 …

Drug Utilizationmedicine.medical_specialtybusiness.industryHospital settingObesity SurgeryGeneral MedicinePrimary careProton pump inhibitorEsomeprazolePrescribing appropriateneSettore MED/02 - Storia Della MedicinaHospitalDrug utilizationSettore BIO/14 - FarmacologiaMedicineMedical prescriptionbusinessIntensive care medicineAdverse effectPrescribed drugsmedicine.drugDDD
researchProduct

Clinical pharmacology and safety profile of esomeprazole, the first enantiomerically pure proton pump inhibitor

2001

Awareness of important differences in the pharmacological profile of individual optical isomers of chiral drugs led to the development of esomeprazole, the S-isomer of omeprazole, a new pharmacological entity designed to improve the clinical outcome of available proton pump inhibitors in the management of acid-related disorders. The superior acid control achieved by esomeprazole is mainly due to an advantageous metabolism compared with racemate omeprazole, leading to improved bioavailability and to enhanced delivery of the drug to the gastric proton pump.

DrugPeptic Ulcermedicine.drug_classmedia_common.quotation_subjectProton-pump inhibitorPharmacologyEsomeprazolelaw.inventionZollinger-Ellison SyndromelawmedicineHumansDrug InteractionsOmeprazoleRandomized Controlled Trials as Topicmedia_commonClinical pharmacologyHepatologybusiness.industryGastroenterologyEsomeprazoleProton Pump InhibitorsAnti-Ulcer AgentsBioavailabilityProton pumpSafety profilebusinessOmeprazolemedicine.drugDigestive and Liver Disease
researchProduct

Minimal Change Esophagitis: Prospective Comparison of Endoscopic and Histological Markers between Patients with Non-Erosive Reflux Disease and Normal…

2004

<i>Introduction:</i> More than half the patients with gastroesophageal reflux disease (GERD) show no endoscopic abnormality or minimal change esophagitis (non-erosive reflux disease, NERD). We investigated the value of endoscopic and histological markers for the prediction of NERD before and after treatment with 20 mg esomeprazole. <i>Methods:</i> Between July and October 2002, consecutive patients presenting for upper endoscopy were stratified into GERD and non-reflux patients (control group) with the help of a questionnaire. The endoscopist was blind to the presence of reflux symptoms. Using magnifying endoscopes minimal change esophagitis was defined by the presen…

Malemedicine.medical_specialtyNerdBiopsySensitivity and SpecificityGastroenterologyPredictive Value of TestsInternal medicinemedicineEsophagitisHumansProspective StudiesEnzyme Inhibitorsskin and connective tissue diseasesProspective cohort studybusiness.industrydigestive oral and skin physiologyGastroenterologyRefluxCase-control studyEsomeprazoleProton Pump InhibitorsGeneral MedicineMiddle AgedAnti-Ulcer Agentsmedicine.diseasehumanitiesdigestive system diseasesCase-Control StudiesPredictive value of testsGERDFemaleEsophagoscopysense organsAbnormalitybusinessEsophagitisDigestive Diseases
researchProduct

Improving opportunities for effective management of gastro-oesophageal reflux disease

2002

The recent introduction of proton pump inhibitors has extraordinarily improved the therapeutic approach to gastro-oesophageal reflux disease. The concept of decreasing gastric acid secretion and increasing the pH in the lower oesophagus has been demonstrated to be therapeutically effective and the higher the level of pH achieved, the better the results. In spite of the evident efficacy of these molecules, there are still many patients who will continue to have symptoms despite medical treatment. Proton pump inhibitors suppress gastric acidity, but this effect shows a remarkable interindividual variation depending on different reasons. Thus, it is still possible to optimise medical therapy f…

medicine.medical_specialtyBiological AvailabilityDiseaseGastroenterologyEsomeprazoleTherapeutic approachIsomerismInternal medicineEsophagitisHumansMedicineOmeprazoleHepatologybusiness.industrydigestive oral and skin physiologyGastroenterologyRefluxEsomeprazoleProton Pump InhibitorsHydrogen-Ion ConcentrationAnti-Ulcer Agentsdigestive system diseasesClinical trialTreatment OutcomeTolerabilityGastric MucosaGastroesophageal RefluxGastric acidbusinessOmeprazolemedicine.drugDigestive and Liver Disease
researchProduct

Pharmacokinetic evaluation of esomeprazole for the treatment of gastroesophageal reflux disease

2014

Proton pump inhibitors (PPIs) are widely used for the treatment of acid-related diseases such as gastroesophageal reflux disease (GERD). They are recommended by the American College of Gastroenterology for healing erosive esophagitis (EO) and as long-term treatment in patients with healed EO. The available PPIs differ somewhat in their pharmacokinetics and clinical properties, but whether these differences are of clinical relevance is a matter of debate. Some safety concerns have been raised with the use of PPIs, mostly an increased incidence of infectious diseases such as community-acquired pneumonia or Clostridium difficile diarrhea.This article explores the results of clinical studies on…

medicine.medical_specialtyDiseaseToxicologyGastroenterologyEsomeprazolePharmacokineticsInternal medicinemedicineEsophagitisHumansClinical significanceIntensive care medicinePharmacologybusiness.industryIncidenceIncidence (epidemiology)Public healthEsomeprazoleProton Pump InhibitorsStereoisomerismGeneral Medicinemedicine.diseasePneumoniaGastroesophageal RefluxGERDbusinessmedicine.drugExpert Opinion on Drug Metabolism & Toxicology
researchProduct

Management strategy for patients with gastroesophageal reflux disease: a comparison between empirical treatment with esomeprazole and endoscopy-orien…

2008

Management Strategy for Patients With Gastroesophageal Reflux Disease: A Comparison Between Empirical Treatment With Esomeprazole and Endoscopy-Oriented Treatment

medicine.medical_specialtyHepatologymedicine.diagnostic_testbusiness.industryEsophageal diseasemedicine.drug_classGastroenterologyRefluxProton-pump inhibitorDiseasemedicine.diseaseGastroenterologyEndoscopyEsomeprazolelaw.inventionQuality of lifeRandomized controlled triallawInternal medicinemedicinebusinessmedicine.drug
researchProduct

Pantoprazole: from drug metabolism to clinical relevance.

2008

Conditions requiring inhibition of acid secretion, such as gastro-oesophageal reflux disease (GORD), peptic ulcers, non-ulcer dyspepsia or the use of NSAIDs, are very common, and their prevalence is expecting to rise as they are seen predominantly amongst the elderly. Among the drugs available to inhibit acid secretion, proton pump inhibitors (PPI) have been shown to have the best efficacy-safety ratio and have been used widely.This paper was intended to provide an overall presentation of one of these PPIs, pantoprazole.This study was first intended to give an overview of pantoprazole, so a Medline search was conducted using pantoprazole as unique search term, without publication date restr…

medicine.medical_specialtyPeptic UlcerPepticRabeprazoleLansoprazoleToxicologyGastroenterology2-PyridinylmethylsulfinylbenzimidazolesEsomeprazoleInternal medicinemedicineHumansPantoprazoleOmeprazolePantoprazolePharmacologyClinical Trials as Topicbiologybusiness.industryProton Pump InhibitorsGeneral MedicineHelicobacter pyloribiology.organism_classificationAnti-Ulcer Agentsdigestive system diseasesTreatment OutcomeGastroesophageal RefluxbusinessDrug metabolismmedicine.drugExpert opinion on drug metabolismtoxicology
researchProduct